The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: This study aimed to identify clinical features associated with premature mortality in a large contemporary cohort of adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: The Finnish Diabetic Nephropathy (FinnDiane) study is a national multicenter prospective follow-up study of 4,201 adults with type 1 diabetes from 21 university and central hospitals, 33 district hospitals, and 26 primary health care centers across Finland. RESULTS: During a median 7 years of follow-up, there were 291 deaths (7%), 3.6-fold (95% CI 3.2–4.0) more than that observed in the age- and sex-matched general population. Excess mortality was only observed in individuals with chronic kidney disease. Individuals with normoalbuminuria showed no excess mortality beyond the general population (standardized mortality ratio [SMR] 0.8, 95% CI 0.5–1.1), independent of the duration of diabetes. The presence of microalbuminuria, macroalbuminuria, and end-stage kidney disease was associated with 2.8, 9.2, and 18.3 times higher SMR, respectively. The increase in mortality across each stage of albuminuria was equivalent to the risk conferred by preexisting macrovascular disease. In addition, the glomerular filtration rate was independently associated with mortality, such that individuals with impaired kidney function, as well as those demonstrating hyperfiltration, had an increased risk of death. CONCLUSIONS: An independent graded association was observed between the presence and severity of kidney disease and mortality in a large contemporary cohort of individuals with type 1 diabetes. These findings highlight the clinical and public health importance of chronic kidney disease and its prevention in the management of type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Diabetic nephropathy, whether manifesting as microalbuminuria, macroalbuminuria, or a reduced glomerular filtration rate progressively augments the overall risk of macrovascular complications.118”
From Type 1 diabetes (2018) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, UACR is a continuous measurement, and differences within the normal and abnormal ranges are associated with kidney and cardiovascular outcomes (6,10,11).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, UACR is a continuous measurement, and differences within the normal and abnormal ranges are associated with kidney and cardiovascular outcomes (6,11,12).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 3×
“9* Any retinopathy 76 (29)† 1,313 (50) 420 (93)† 290 (99)† Retinopathy requiring laser therapy 27 (10)† 683 (25) 360 (78)† 288 (97)† Current smoker 98 (37)† 614 (24) 95 (22) 49 (16)† Established macrovascular disease 31 (11)† 123 (5) 116 (25)† 138 (47)† Macroalbuminuria 2 (3)† 210 (8) 338 (73)† N/A Microalbuminuria 2…”
MethodIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Goodpasture syndrome during the course of a Schönlein-Henoch purpura
Carreras, L., Poveda, R., Bas, J., Mestre, M., Rama, I., & Carrera, M. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32799 · Cited by 1,474
Albuminuria reflects widespread vascular damage: The Steno hypothesis
Deckert, T., Feldt-Rasmussen, B., Borch-Johnsen, K., Jensen, T., & Kofoed-Enevoldsen, A. (1989) · Diabetologia · doi:10.1007/bf00285287 · Cited by 1,400
Doqi, K. (2002) · American Journal of Kidney Diseases · Cited by 1,285
Global guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
Conditioning Diagnostics: Collinearity and Weak Data in Regression
Goldstein, R. (1993) · Technometrics · doi:10.1080/00401706.1993.10484997 · Cited by 911
(2004) · doi:10.1177/0049124103262065 · Cited by 906
Cited by
Items 201–300 of 651
Kwiatkowski, A. J., Stewart, J. M., Cho, J. J., Avram, D., & Keselowsky, B. G. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000164 · Cited by 44
Penno, G., Orsi, E., Solini, A., Bonora, E., Fondelli, C., Trevisan, R., Vedovato, M., Cavalot, F. L., Gruden, G., Laviola, L., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001481 · Cited by 46
Pacilli, A., Viazzi, F. C., Fioretto, P., Giorda, C. B., Ceriello, A., Genovese, S., Russo, G. T., Guida, P., Pontremoli, R., Cosmo, S. D., et al. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2873 · Cited by 44
Finne, P., Groop, P., Arffman, M., Kervinen, M., Helve, J., Grönhagen‐Riska, C., & Sund, R. (2019) · Diabetes Care · doi:10.2337/dc18-1485 · Cited by 45
Self-citationArterial Stiffness Predicts Mortality in Individuals With Type 1 Diabetes
Tynjälä, A., Forsblom, C. M., Harjutsalo, V., Groop, P., & Gordin, D. (2020) · Diabetes Care · doi:10.2337/dc20-0078 · Cited by 46
Self-citationon behalf of the FinnDiane Study Group, Sigfrids, F. J., Forsblom, C. M., Harjutsalo, V., Thorn, L. M., Wadén, J., Elonen, N., Ahola, A. J., Saraheimo, M., & Groop, P. (2018) · Diabetologia · doi:10.1007/s00125-018-4564-8 · Cited by 47
Self-citationElliott, M. D., Heitner, J. F., Kim, H., Wu, E., Parker, M. A., Lee, D. C., Kaufman, D. B., Bonow, R. O., Judd, R. M., & Kim, R. J. (2019) · Diabetes Care · doi:10.2337/dc18-2266 · Cited by 44
Gordin, D., Soro‐Paavonen, A., Thomas, M. C., Harjutsalo, V., Saraheimo, M., Bjerre, M., Forsblom, C. M., Flyvbjerg, A., Groop, P., & on behalf of the FinnDiane Study Group (2013) · Diabetes Care · doi:10.2337/dc12-2170 · Cited by 40
Self-citationParente, E. B., Harjutsalo, V., Forsblom, C. M., Groop, P., & on behalf of The FinnDiane Study Group (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01340-4 · Cited by 40
Self-citationGordin, D., Kaaja, R., Forsblom, C. M., Hiilesmaa, V. K., Teramo, K. A., & Groop, P. (2012) · Acta Diabetologica · doi:10.1007/s00592-012-0415-0 · Cited by 43
Self-citationFarmer, A. A., Stevens, R., Hirst, J. A., Lung, T. W.-C., Oke, J. L., Clarke, P., Glasziou, P., Neil, A., Dunger, D. B., Colhoun, H. M., et al. (2014) · Health Technology Assessment · doi:10.3310/hta18140 · Cited by 44
“It is expensive to treat and kidney disease progression is a marker of subsequent morbidity and mortality.(11) In the UK in 2004, the total annual NHS costs for managing diabetic kidney disease were reported as £152M for type 1 diabetes and £614M for type 2 diabetes.”
BackgroundPanduru, N. M., Saraheimo, M., Forsblom, C. M., Thorn, L. M., Gordin, D., Wadén, J., Tolonen, N., Bierhaus, A., Humpert, P. M., & Groop, P. (2015) · Diabetes Care · doi:10.2337/dc14-2276 · Cited by 40
Self-citationBjerg, L., Hulman, A., Carstensen, B., Charles, M., Witte, D. R., & Jørgensen, M. E. (2019) · Diabetologia · doi:10.1007/s00125-019-4812-6 · Cited by 39
Nabrdalik, K., Kwiendacz, H., Moos, J., Moos, Ł., Kulpa, J., Brzoza, Z., Stompór, T. P., Gumprecht, J., & Lip, G. Y. H. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101726 · Cited by 48
Alterations of urinary metabolite profile in model diabetic nephropathy
Stec, D. F., Wang, S., Stothers, C. L., Avance, J., Denson, D., Harris, R. C., & Voziyan, P. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.12.003 · Cited by 38
Leti, F., Morrison, E. J., & DiStefano, J. K. (2017) · Personalized Medicine · doi:10.2217/pme-2016-0107 · Cited by 38
Palanca, A., Castelblanco, E., Perpiñán, H., Betriu, À., Soldevila, B., Valdivielso, J. M., Bermúdez-López, M., Durán, X., Fernández, E., Puig‐Domingo, M., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.018 · Cited by 39
Self-citationPresent and future directions in diabetic kidney disease
Limonte, C. P., Kretzler, M., Pennathur, S., Pop‐Busui, R., & de Boer, I. H. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108357 · Cited by 39
Orchard, T. J., Sun, W., Cleary, P. A., GENUTH, S. M., Lachin, J. M., McGee, P., Paterson, A. D., Raskin, P., Anbinder, Y., & Levy, A. P. (2013) · Diabetes · doi:10.2337/db13-0256 · Cited by 37
Hamet, P., Haloui, M., Harvey, F., Marois-Blanchet, F.-C., Sylvestre, M., Tahir, R., Simon, P. H. G., Kanzki, B., Raelson, J., Long, C., et al. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001241 · Cited by 43
Progress in Defining the Genetic Basis of Diabetic Complications
Dahlström, E. H., & Sandholm, N. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0906-z · Cited by 38
Baek, J. H., Lee, W. J., Lee, B., Kim, S. Y., Kim, G., Jin, S., & Kim, J. H. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0134 · Cited by 39
Zhang, Q., Xu, S., Qian, J., Yang, L., Chen, P., Wang, Y., Hu, X., Zhang, Y., Luo, W., & Liang, G. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00766-6 · Cited by 37
Lay, A. C., Tran, V. D. T., Nair, V., Betin, V. M. S., Hurcombe, J., Barrington, A. F., Pope, R. J. P., Burdet, F., Mehl, F., Kryvokhyzha, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54089-1 · Cited by 38
Preventing Cardiovascular Complications in Type 1 Diabetes: The Need for a Lifetime Approach
Chiesa, S. T., & Marcovecchio, M. L. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.696499 · Cited by 36
Foam cells and the pathogenesis of kidney disease
Eom, M., Hudkins, K. L., & Alpers, C. E. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000112 · Cited by 37
Specialized pro-resolving mediators in renal fibrosis
Brennan, E. P., Cacace, A., & Godson, C. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.05.001 · Cited by 36
Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study
Townsend, R. R., Guarnieri, P., Argyropoulos, C., Blady, S. J., Boustany, C., Devalaraja-Narashimha, K. B., Morton, L. G., Mottl, A. K., Patel, U. D., Palmer, M., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.09.020 · Cited by 36
Cook, S., Schmedt, N., Broughton, J., Kalra, P. A., Tomlinson, L. A., & Quint, J. K. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-065927 · Cited by 39
Diabetic nephropathy: new approaches for improving glycemic control and reducing risk
Schernthaner, G., & Schernthaner, G.-H. (2013) · Journal of Nephrology · doi:10.5301/jn.5000281 · Cited by 39
Genetic basis of diabetic kidney disease and other diabetic complications
Sandholm, N., & Groop, P. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.01.002 · Cited by 35
Self-citationLuo, W., Tang, S., Xiao, X., Luo, S., Yang, Z., Huang, W., & Tang, S. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s408170 · Cited by 36
Song, S., Qiu, D., Wang, Y., Wei, J., Wu, H., Wu, M. T., Wang, S., Zhou, X., Shi, Y., & Duan, H. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.111862 · Cited by 36
Liu, G., Shea, C. M., Jones, J. E., Price, G. M., Warren, W., Lonie, E., Yan, S., Currie, M. G., Profy, A. T., Masferrer, J. L., et al. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00003.2020 · Cited by 40
Murray, R., Zimmerman, T., Agarwal, A., Palevsky, P. M., Quaggin, S. E., Rosas, S. E., & Kramer, H. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.04.006 · Cited by 37
Griffin, T. P., O’Shea, P. M., Smyth, A., Islam, M. N., Wall, D., Ferguson, J. P., O'Sullivan, E., Finucane, F. M., Dinneen, S. F., Dunne, F., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002125 · Cited by 38
Katz, M. L., Giani, E., & Laffel, L. M. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0692-4 · Cited by 38
Skin autofluorescence predicts cardio-renal outcome in type 1 diabetes: a longitudinal study
Vélayoudom‐Céphise, F., Rajaobelina, K., Helmer, C., Nov, S., Pupier, É., Blanco, L., Hugo, M., Farges, B., Astrugue, C., Gin, H., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0448-8 · Cited by 34
Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease
Piko, N., Bevc, S., Hojs, R., & Ekart, R. (2024) · Pharmaceuticals · doi:10.3390/ph17040418 · Cited by 37
“It appears that the excess mortality in diabetic patients is mostly present in those with accompanying CKD [36].”
BackgroundA new strategy for vascular complications in young people with type 1 diabetes mellitus
on behalf of the Adolescent type 1 Diabetes cardio-renal Intervention Trial (AdDIT) study group, Marcovecchio, M. L., Dalton, R. N., Daneman, D., Deanfield, J. E., Jones, T. W., Neil, H. A. W., & Dunger, D. B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0198-2 · Cited by 34
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus
Oktay, A. A., Aktürk, H. K., Esenboğa, K., Javed, F., Polin, N. M., & Jahangir, E. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.05.001 · Cited by 36
“between risk of all-cause mortality and severity of DKD, from microalbuminuria to macroalbuminuria to ESRD.(234) The HOPE (Heart Outcomes Prevention Evaluation) study showed that presence of”
BackgroundState of the art paper Influence of lifestyle on the course of type 1 diabetes mellitus
Piłaciński, S., & Zozulińska‐Ziółkiewicz, D. (2014) · Archives of Medical Science · doi:10.5114/aoms.2014.40739 · Cited by 44
“In the FinnDiane study, the 7-year mortality in patients with T1DM was three times higher than in the general population, although the difference disappeared after excluding patients with nephropathy [8].”
BackgroundLi, X., Liu, J., Lu, L., Huang, T., Hou, W., Wang, F., Yu, L., Wu, F., Qi, J., Chen, X., et al. (2022) · Translational research · doi:10.1016/j.trsl.2022.04.005 · Cited by 31
Hallström, S., Wijkman, M. O., Ludvigsson, J., Ekman, P., Pfeffer, M. A., Wedel, H., Rosengren, A., & Lind, M. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100469 · Cited by 40
“17,18 Despite the impact of these risk factors as well as cardiovascular disease most investigations of whether prognosis improve over time generally treat T1D patients as a homogenous group.”
Tolonen, N., Forsblom, C. M., Mäkinen, V., Harjutsalo, V., Gordin, D., Feodoroff, M., Sandholm, N., Thorn, L. M., Wadén, J., Taskinen, M., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2873 · Cited by 34
Self-citationInfluence of HbA1c and BMI on Lipid Trajectories in Youths and Young Adults With Type 1 Diabetes
Katz, M. L., Kollman, C., Dougher, C. E., Mubasher, M., & Laffel, L. M. (2016) · Diabetes Care · doi:10.2337/dc16-0430 · Cited by 32
Chantzichristos, D., Persson, A., Eliasson, B., Miftaraj, M., Franzén, S., Bergthorsdottir, R., Gudbjörnsdottir, S., Svensson, A.-M., & Johannsson, G. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0657 · Cited by 30
Renal Function Is Associated With Peak Exercise Capacity in Adolescents With Type 1 Diabetes
Bjornstad, P., Cree‐Green, M., Baumgartner, A., Maahs, D. M., Cherney, D. Z. I., Pyle, L. L., Regensteiner, J. G., Reusch, J. E. B., & Nadeau, K. J. (2014) · Diabetes Care · doi:10.2337/dc14-1742 · Cited by 30
Diabetes and intracerebral hemorrhage: baseline characteristics and mortality
Liebkind, R., Gordin, D., Strbian, D., Meretoja, A., Thorn, L. M., Hägg-Holmberg, S., Forsblom, C. M., Tatlisumak, T., Groop, P., & Putaala, J. (2018) · European Journal of Neurology · doi:10.1111/ene.13603 · Cited by 30
“This is of special interest as it is known that the fate of patients with T2D is related to a number of atherogenic risk factors such as dyslipidemia, hypertension and insulin resistance, whereas CKD seems to be the key driver of mortality in T1D [24].”
BackgroundSelf-citationGordin, D., Harjutsalo, V., TINSLEY, L. J., Fickweiler, W., Sun, J. K., Forsblom, C. M., Amenta, P. S., POBER, D. M., D’Eon, S., Khatri, M., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2250 · Cited by 32
Self-citationDepression Is Associated With Progression of Diabetic Nephropathy in Type 1 Diabetes
Ahola, A. J., Harjutsalo, V., Forsblom, C. M., Pouwer, F., Groop, P., & the FinnDiane Study Group (2020) · Diabetes Care · doi:10.2337/dc20-0493 · Cited by 31
Self-citationExercise and nutrition in type 1 diabetes: Insights from the FinnDiane cohort
Barlovič, D. P., Harjutsalo, V., & Groop, P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1064185 · Cited by 34
“Moreover, we have shown that also in individuals with diabetic nephropathy, which is one of the main determinants of premature mortality in type 1 diabetes (11), total LTPA as well as all its components were associated with decreased all-cause mortality, independently of a series of confounders (10).”
BackgroundSelf-citationLuppi, P., Kallas, Å., & Wahren, J. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2409 · Cited by 29
Complications of Diabetes Mellitus
Brownlee, M., Aiello, L. P., Cooper, M. E., Vinik, A. I., Plutzky, J., & Boulton, A. J. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00033-2 · Cited by 43
Urinary Plasmin(ogen) as a Prognostic Factor for Hypertension
Ray, E. C., Miller, R. G., Demko, J. E., Costacou, T., Kinlough, C. L., Demko, C. L., Unruh, M. L., Orchard, T. J., & Kleyman, T. R. (2018) · Kidney International Reports · doi:10.1016/j.ekir.2018.06.007 · Cited by 29
“We have previously shown in the EDC cohort that excess mortality is statistically explained by increased albuminuria,(43) consistent with earlier data from the FinnDiane study.(46) It is intriguing that, in the present study, individuals experiencing cardiovascular mortality had elevated baseline plasmin(ogen).”
ResultEmerging Targets for Cardiovascular Disease Prevention in Diabetes
Stitziel, N. O., Kanter, J. E., & Bornfeldt, K. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.03.011 · Cited by 30
Derebail, V. K., Zhou, Q., Ciccone, E. J., Cai, J., & Ataga, K. I. (2019) · British Journal of Haematology · doi:10.1111/bjh.16003 · Cited by 28
Schweiger, D. Š., Battelino, T., & Grošelj, U. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910192 · Cited by 30
Endothelin in Diabetic Renal Disease
Benz, K., & Amann, K. (2011) · Contributions to nephrology · doi:10.1159/000328695 · Cited by 28
Zhao, Y. D., Chen, S.-J., Wang, J., Niu, H., Jia, Q.-Q., Chen, X., Du, X., Lu, L., Huang, B., Zhang, Q., et al. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/934058 · Cited by 32
Gordin, D., & Groop, P. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816636894 · Cited by 31
“This is in line with the observation that diabetic nephropathy is the main contributor to premature death in these patients.(26)”
ResultSelf-citationAhola, A. J., Gordin, D., Forsblom, C. M., & Groop, P. (2018) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2018.07.003 · Cited by 29
Self-citationPredictors of and survival after incident stroke in type 1 diabetes
Secrest, A. M., Prince, C. T., Costacou, T., Miller, R. G., & Orchard, T. J. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112441006 · Cited by 33
Lai, S. W. T., Hernandez-Castillo, C., Gonzalez, E. D. J. L., Zoukari, T., Talley, M., Paquin, N., Chen, Z., Roep, B. O., Kaddis, J. S., Natarajan, R. D., et al. (2023) · Diabetes · doi:10.2337/db23-0277 · Cited by 27
Fountoulakis, N., Miyamoto, Y., Pavkov, M. E., Karalliedde, J. J., & Maltese, G. (2024) · Diabetic Medicine · doi:10.1111/dme.15464 · Cited by 31
YKL‐40 in type 2 diabetic patients with different levels of albuminuria
Brix, J. M., Höllerl, F., Koppensteiner, R., Schernthaner, G., & Schernthaner, G.-H. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02446.x · Cited by 27
Ortiz, F., Harjutsalo, V., Helanterä, I., Lempinen, M., Forsblom, C. M., & Groop, P. (2018) · Diabetes Care · doi:10.2337/dc18-1029 · Cited by 29
Self-citationBebu, I., Braffett, B. H., de Boer, I. H., Aiello, L. P., Bantle, J. P., Lorenzi, G. M., Herman, W. H., Gubitosi‐Klug, R., Perkins, B. A., Lachin, J. M., et al. (2022) · Diabetes Care · doi:10.2337/dc22-1744 · Cited by 29
Raman, S., Dai, H. D., DeLurgio, S. A., Williams, D. D., Lind, M., Patton, S. R., Spertus, J. A., Kosiborod, M., & Clements, M. A. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12300 · Cited by 27
Glycation in diabetic nephropathy
Forbes, J. M., & Cooper, M. E. (2010) · Amino Acids · doi:10.1007/s00726-010-0771-4 · Cited by 28
“The microvascular complications include kidney disease, arguably the most important predictor for both subsequent cardiovascular disease and all-cause mortality (Groop et al. 2009; Matsushita et al. 2010).”
BackgroundCardiovascular complications of type 1 diabetes: update on the renal link
Orchard, T. J., & Costacou, T. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0949-7 · Cited by 29
Mahmud, F. H., Bjornstad, P., Clarson, C. L., Clarke, A. B. M., Anthony, S. J., Curtis, J., Elia, Y. T., McArthur, L., Mertens, L., Moineddin, R., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03723-6 · Cited by 27
“Clinical evidence of CKD does not typically present in adolescence, but supraphysiologic increases in GFR occur early in T1D and may reflect underlying changes in glomerular pressure and hyperfiltration 16–18 .”
Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities
Aboolian, A., Urner, S., Roden, M., Jha, J. C., & Jandeleit-Dahm, K. A. M. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_576 · Cited by 28
Gallagher, H., Dumbleton, J., Maishman, T., Whitehead, A. L., Moore, M. V., Fuat, A., Fitzmaurice, D. A., Henderson, R. A., Lord, J., Griffith, K. E., et al. (2022) · Trials · doi:10.1186/s13063-022-06132-z · Cited by 26
Age and Sex Influence Cystatin C in Adolescents With and Without Type 1 Diabetes
Maahs, D. M., Prentice, N., McFann, K., Snell‐Bergeon, J. K., Jalal, D. I., Bishop, F. K., Aragón, B. A., & Wadwa, R. P. (2011) · Diabetes Care · doi:10.2337/dc11-0829 · Cited by 25
“Early identification of incipient diabetic kidney disease and risk stratification for who will progress to clinical diabetic nephropathy remains a major research priority for preventing diabetes complications, including renal disease itself (1), and as a risk factor for cardiovascular disease and mortality (8,9).”
BackgroundVerkauskienė, R., Danytė, E., Dobrovolskienė, R., Stankutė, I., Šimonienė, D., Ražanskaitė-Virbickienė, D., Šeibokaitė, A., Urbonaitė, B., Jurgevičienė, N., Vitkauskienė, A., et al. (2016) · BMC Endocrine Disorders · doi:10.1186/s12902-016-0145-3 · Cited by 25
ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE
Liew, A., Bavanandan, S., Prasad, N., Wong, M. G., Chang, J. M., Eiam‐Ong, S., Hao, C., Lim, C. Y., Lim, S. K., Oh, K., et al. (2020) · Nephrology · doi:10.1111/nep.13785 · Cited by 24
Sambo, F., The FinnDiane Study Group, Malovini, A. L., Sandholm, N., Stavarachi, M., Forsblom, C. M., Mäkinen, V., Harjutsalo, V., Lithovius, R., Gordin, D., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3256-2 · Cited by 26
Self-citationTikellis, C., Pickering, R. J., Tsorotes, D., Harjutsalo, V., Thorn, L. M., Ahola, A. J., Wadén, J., Tolonen, N., Saraheimo, M., Gordin, D., et al. (2012) · Clinical Science · doi:10.1042/cs20120352 · Cited by 23
Self-citationGetting a Notch Closer to Understanding Diabetic Kidney Disease
Ahn, S.-H., & Suszták, K. (2010) · Diabetes · doi:10.2337/db10-0077 · Cited by 23
van Raalte, D. H., & Bjornstad, P. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz228 · Cited by 24
Davis, T. M. E., Chubb, S. A. P., & Davis, W. A. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0327 · Cited by 23
Metformin Protects against Podocyte Injury in Diabetic Kidney Disease
Lehtonen, S. H. (2020) · Pharmaceuticals · doi:10.3390/ph13120452 · Cited by 24
the FinnDiane Study Group, Ahola, A. J., Harjutsalo, V., Saraheimo, M., Forsblom, C. M., & Groop, P. (2011) · Diabetologia · doi:10.1007/s00125-011-2347-6 · Cited by 23
“Diabetes, among other causes, significantly contributes to premature death related to cardiovascular [3] and kidney diseases [4].”
BackgroundSelf-citationBjornstad, P., Pyle, L. L., Kinney, G. L., Rewers, M., Johnson, R. J., Maahs, D. M., & Snell‐Bergeon, J. K. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.06.012 · Cited by 22
“73 m2, represents a magnitude of change 3 times the rate expected in normal physiology (Groop et al., 2009; Krolewski et al., 2013).”
BackgroundInfluentialDuration of diabetes-related complications and mortality in type 1 diabetes: a national cohort study
Bjerg, L., Guðbjörnsdóttir, S., Franzén, S., Carstensen, B., Witte, D. R., Jørgensen, M. E., & Svensson, A. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyaa290 · Cited by 25
The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
Thomas, M. C., Jandeleit-Dahm, K. A. M., & Tikellis, C. (2012) · PPAR Research · doi:10.1155/2012/456529 · Cited by 22
Self-citationData-driven metabolic subtypes predict future adverse events in individuals with type 1 diabetes
on behalf of the FinnDiane Study Group, Lithovius, R., Toppila, I., Harjutsalo, V., Forsblom, C. M., Groop, P., & Mäkinen, V. (2017) · Diabetologia · doi:10.1007/s00125-017-4273-8 · Cited by 23
“The acute symptoms of type 1 diabetes can be managed by insulin therapy, but a significant number of individuals gradually develop chronic diabetic complications that reduce the quality of life [1], cause most of the public health burden [2] and shorten life expectancy [3].”
BackgroundSelf-citationHariyanto, I., Hsieh, C., Hsu, Y., Chen, L.-G., Chu, C., & Weng, B. B. (2022) · Life · doi:10.3390/life12111716 · Cited by 21
Poulsen, C., Jesse, K., Carstensen, B., Frimodt‐Møller, M., Hansen, T. W., Persson, F., Vistisen, D., & Rossing, P. R. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.09.010 · Cited by 21
Competing Risk of Death With End-Stage Renal Disease in Diabetic Kidney Disease
Jiang, Y., Fine, J. P., & Mottl, A. K. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2018.01.008 · Cited by 22
Cummings, L. A. M., Clarke, A. B. M., Sochett, E. B., Daneman, D., Cherney, D. Z. I., Reich, H. N., Scholey, J. W., Dunger, D. B., & Mahmud, F. H. (2018) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2018.03.030 · Cited by 21
Mortality in Type 1 Diabetes in the Current Era: Two Steps Forward, One Step Backward
Katz, M. L., & Laffel, L. M. (2015) · JAMA · doi:10.1001/jama.2014.16327 · Cited by 26
SHAH, A. S., Dolan, L. M., Lauer, A., Davis, C., Dabelea, D., Daniels, S. R., Hamman, R. F., Marcovina, S., Wadwa, R. P., & Urbina, E. M. (2012) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2012-0070 · Cited by 20
Association between depressive symptoms and dietary intake in patients with type 1 diabetes
Ahola, A. J., Forsblom, C. M., & Groop, P. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.018 · Cited by 23
Self-citationImportance of Identifying Novel Biomarkers of Microvascular Damage in Type 1 Diabetes
Marcovecchio, M. L. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00483-6 · Cited by 20
Simonsen, J. R., Järvinen, A., Hietala, K., Harjutsalo, V., Forsblom, C. M., Groop, P., & Lehto, M. J. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316202 · Cited by 20
Self-citationCarino, M., Elia, Y. T., Sellers, E. A. C., Curtis, J., McGavock, J., Scholey, J. W., Hamilton, J. K., Clarson, C. L., Pinto, T. E., Hadjiyannakis, S., et al. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.01.008 · Cited by 20
Buckley, L. F., Schmidt, I. M., Verma, A., Pálsson, R., Adam, D., Shah, A. M., Srivastava, A., & Waikar, S. S. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.0056 · Cited by 21
Sejling, A., Schouwenberg, B., Færch, L., Thorsteinsson, B., de Galan, B. E., & Pedersen‐Bjergaard, U. (2015) · Diabetic Medicine · doi:10.1111/dme.12810 · Cited by 24
Metadata
- Authors
- Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., & Forsblom, C.
- Affiliations
- Helsinki University Hospital (FI)
- Baker Heart and Diabetes Institute (AU)
- Department of Intensive Care Medicine, The Queen Elizabeth Hospital, Woodville, South Australia, Australia;
- Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland;
- Corresponding author
- Groop, Per-Henrik
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-04-28
- Volume
- 58
- Issue
- 7
- Pages
- 1651-1658
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2699848
- OpenAlex
- W2101457616
- Semantic Scholar
- 8c94474962d440b785728afdfb3a4ed830eedf9d
- Cited by
- 638
- References
- 49
- Citations by year
- 2026: 14 · 2025: 29 · 2024: 30 · 2023: 38 · 2022: 59 · 2021: 43 · 2020: 40 · 2019: 48 · 2018: 55 · 2017: 43 · 2016: 40 · 2015: 41 · 2014: 54 · 2013: 40 · 2012: 23
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by-nc-nd)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- Funders
- Wilhelm och Else Stockmanns Stiftelse
- European Commission
- Signe ja Ane Gyllenbergin Säätiö
- Waldemar von Frenckells Stiftelse
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 1 diabetes, chronic kidney disease, all-cause mortality, diabetic nephropathy, albuminuria, microalbuminuria, macroalbuminuria, end-stage renal disease, glomerular filtration rate, hyperfiltration, standardized mortality ratio
- MeSH terms
- Adolescent, Adult, Cause of Death, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Female, Finland, Follow-Up Studies, Glomerular Filtration Rate, Humans, Insulin, Male, Middle Aged, Severity of Illness Index, Cohort Studies, Age of Onset, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.